Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

被引:248
作者
Gubareva, LV
Kaiser, L
Matrosovich, MN
Soo-Hoo, Y
Hayden, FG
机构
[1] Univ Virginia, Sch Med, Dept Internal Med, Div Epidemiol & Virol, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA
[3] St Jude Childrens Res Hosp, Dept Virol & Mol Biol, Memphis, TN 38105 USA
[4] Russian Acad Med Sci, MP Chumakov Inst Poliomyelitis & Virus Encephalit, Moscow, Russia
关键词
D O I
10.1086/318537
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Volunteers experimentally infected with influenza A/Texas/36/91 (H1N1) virus and treated with the neuraminidase (NA) inhibitor oseltamivir were monitored for the emergence of drug-resistant variants. Two (4%) of 54 resistant viruses were detected by NA inhibition assay among last-day isolates recovered from 54 drug recipients. They bore a substitution His274Tyr in the NA. Hemagglutinin (HA) variants detected in the placebo group differed from the egg-adapted inoculum virus by virtue of amino acid substitutions at residues 137, 225, or both. These variants had a higher affinity for Neu5Ac(alpha2-6)Gal-containing receptors, which are characteristic of human respiratory epithelium, than for Neu5Ac(alpha2-3)Gal-containing receptors, which are typical of chicken egg allantoic membrane. Although appearing to be more sensitive to oseltamivir in humans, the variants with increased affinity for Neu5Ac(alpha2-6)Gal receptors were less sensitive than the Neu5Ac(alpha2-3)Gal-binding variants in Madin-Darby canine kidney cells. Thus, HA affinity for receptors is an essential feature of influenza virus susceptibility to NA inhibitors, both in cell culture and in humans.
引用
收藏
页码:523 / 531
页数:9
相关论文
共 42 条
[1]   The HA1 of cold-adapted influenza B vaccine is not altered during replication in human vaccinees [J].
Abbasi, S ;
Gruber, W ;
Edwards, K ;
Gubareva, L ;
Webster, RG ;
Kawaoka, Y .
VIRUS RESEARCH, 1995, 39 (2-3) :377-383
[2]   MUCINS AND MUCOIDS IN RELATION TO INFLUENZA VIRUS ACTION .6. GENERAL DISCUSSION [J].
ANDERSON, SG ;
BURNET, FM ;
GROTH, SFD ;
MCCREA, JF ;
STONE, JD .
AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 1948, 26 (05) :403-411
[3]   Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140 [J].
Bantia, S ;
Ghate, AA ;
Ananth, SL ;
Babu, YS ;
Air, GM ;
Walsh, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :801-807
[4]  
BANTIA S, 2000, 13 INT C ANT RES BAL, pA60
[5]   In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir [J].
Barnett, JM ;
Cadman, A ;
Burrell, FM ;
Madar, SH ;
Lewis, AP ;
Tisdale, M ;
Bethell, R .
VIROLOGY, 1999, 265 (02) :286-295
[6]  
BAUM LG, 1990, ACTA HISTOCHEM, P35
[7]   The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en [J].
Blick, TJ ;
Sahasrabudhe, A ;
McDonald, M ;
Owens, IJ ;
Morley, PJ ;
Fenton, RJ ;
McKimm-Breschkin, JL .
VIROLOGY, 1998, 246 (01) :95-103
[8]   Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en [J].
Blick, TJ ;
Tiong, T ;
Sahasrabudhe, A ;
Varghese, JN ;
Colman, PM ;
Hart, GJ ;
Bethell, RC ;
McKimmBreschkin, JL .
VIROLOGY, 1995, 214 (02) :475-484
[9]  
CARR J, 2000, 13 INT C ANT RES BAL, pA59
[10]   RECEPTOR SPECIFICITY IN HUMAN, AVIAN, AND EQUINE H2 AND H3 INFLUENZA-VIRUS ISOLATES [J].
CONNOR, RJ ;
KAWAOKA, Y ;
WEBSTER, RG ;
PAULSON, JC .
VIROLOGY, 1994, 205 (01) :17-23